recro_logo.jpg
Recro Pharma Reports Year End 2016 Financial Results
March 06, 2017 16:05 ET | Recro Pharma, Inc.
      Reports 2016 Revenues of $69.3 Million Exceeding Previously Provided Guidance      On Track to File NDA with U.S. FDA for IV Meloxicam in Summer 2017 ...
recro_logo.jpg
Recro Pharma Appoints Bryan Reasons to Its Board of Directors
March 06, 2017 07:00 ET | Recro Pharma, Inc.
MALVERN, Pa., March 06, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and other acute care...
recro_logo.jpg
Recro Pharma to Present at Upcoming Investor Conferences
March 02, 2017 07:00 ET | Recro Pharma, Inc.
MALVERN, Pa., March 02, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care...
recro_logo.jpg
Recro Pharma Completes Enrollment in Phase III Safety Study of IV Meloxicam
February 27, 2017 07:00 ET | Recro Pharma, Inc.
MALVERN, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and other acute care...
recro_logo.jpg
Recro Pharma Announces Closing of $40 Million Public Offering of Common Stock
December 16, 2016 09:26 ET | Recro Pharma, Inc.
MALVERN, Pa., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro” or the “Company”) (Nasdaq:REPH), a revenue-generating, specialty pharmaceutical company primarily focused on developing...
recro_logo.jpg
Recro Pharma Announces Pricing of Public Offering of Common Stock
December 13, 2016 09:09 ET | Recro Pharma, Inc.
MALVERN, Pa., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro” or the “Company”) (Nasdaq:REPH), a revenue-generating, specialty pharmaceutical company primarily focused on developing...
recro_logo.jpg
Recro Pharma Announces Proposed Public Offering of Common Stock
December 08, 2016 09:02 ET | Recro Pharma, Inc.
MALVERN, Pa., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro” or the “Company”) (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital...
recro_logo.jpg
Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam
November 28, 2016 07:00 ET | Recro Pharma, Inc.
IV Meloxicam Achieves Primary Endpoint of Statistically Significant Reduction in SPID24 in Patients with Acute Postoperative Pain Following Abdominoplasty SurgeryTen Secondary Endpoints Also...
recro_logo.jpg
Recro Pharma Reports Third Quarter 2016 Financial Results
November 10, 2016 07:00 ET | Recro Pharma, Inc.
Announced Positive Phase III Results from Pivotal Trial of IV Meloxicam Following Bunionectomy Surgery Pivotal Phase III Trial of IV Meloxicam Following Mini Abdominoplasty Surgery Ongoing;...
recro_logo.jpg
Recro Pharma to Present at Upcoming Investor Conferences
November 09, 2016 07:00 ET | Recro Pharma, Inc.
MALVERN, Pa., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro” or the “Company”) (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital...